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 Body Composition After Endogenous (Cushing ’ s 
Syndrome) and Exogenous (Rheumatoid Arthritis) 
Exposure to Glucocorticoids 
abolition of the normal male to female diﬀ erence 
in visceral fat  [5] . It has been assumed that reso-
lution of hypercortisolism is followed by normal-
ization of body composition; a decrease in fat 
mass has been reported in the early recovery 
after successful treatment of CS  [6,  7] . However, 
patients who have suﬀ ered from CS, often com-
plain of central obesity, despite successful treat-
ment, which may even have rendered them 
adrenal insuﬃ  cient. Persistence of increased car-
diovascular risk and carotid atherosclerosis has 
been reported in patients with CS after fi ve years 
of cure  [8] . Moreover, there could be a relation-
ship between cortisol and fasting glucose  [9] . 
 Rheumatoid arthritis (RA) is a chronic, systemic 
infl ammatory disorder that may aﬀ ect many tis-
sues and organs, but principally attacks the joints 
producing an infl ammatory synovitis that often 
progresses to destruction of the articular carti-
 Introduction 
 ▼ 
 Exposure to chronic glucocorticoid (GC) excess 
produces marked changes in body composition, 
reducing bone mass and lean body mass, and 
favoring central fat accumulation  [1,  2] . Cushing ’ s 
syndrome (CS) is a rare endocrine disease char-
acterized by cortisol hypersecretion, mainly by a 
pituitary tumor (Cushing ’ s disease) or, less fre-
quently, by an adrenal or an ectopic neuroendo-
crine tumor. Changes in body composition in CS 
include increased fat mass, decreased bone mass, 
thinning of the skin, and reduced lean mass. Why 
these tissues are aﬀ ected so dramatically is 
unclear  [3] . Glucocorticoids (GCs) regulate lipid 
metabolism through promoting lipogenesis in 
adipose tissue  [4] . 
 An increase in visceral fat in both male and female 
patients with CS has been reported, with the 
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 Abstract 
 ▼ 
 Exposure to chronic glucocorticoid (GC) excess 
determines changes in body composition. The 
aim of the study was to compare body composi-
tion in women exposed to endogenous hypercor-
tisolism (Cushing ’ s syndrome, CS), and exogenous 
glucocorticoid treatment (rheumatoid arthritis, 
RA) and controls. 51 CS women, 26 RA women 
treated with low-dose prednisone (5  mg / day 
or 10  mg / 2 days), and 78 female controls were 
included. 14 CS patients were hypercortisolemic, 
37 in remission (10 required hydrocortisone 
substitution after surgery). Body composition 
parameters were measured by dual-energy X-
ray absorptiometry scanning (DEXA). RA patients 
had a greater waist-hip ratio (WHR) (p  <  0.01), 
less lean body mass (LBM) (p  <  0.01), and lum-
bar bone mineral density (BMD) (p  <  0.01) than 
controls. CS patients, globally and those with 
cured disease, had more total fat (both percent-
age and kg) and trunk fat percentage, and less 
whole body-BMD than RA patients (p  <  0.05, 
p  <  0.01, p  <  0.05, respectively). Active CS patients 
had less whole body-BMD and more LBM than 
RA patients (p  <  0.05, p  =  0.01, respectively). 
Cured CS patients not taking hydrocortisone had 
more total fat [both percentage (p  <  0.05) and kg 
(p  <  0.05)], trunk fat percentage (p  <  0.05), lum-
bar BMD (p  <  0.01) than RA patients. Cured CS 
patients requiring hydrocortisone only diﬀ ered 
from RA patients by smaller WHR (p  <  0.01). All 
the diﬀ erences in BMD disappeared when the 
data were reanalyzed including only the estro-
gen-defi cient groups. Hypercortisolism of CS 
determines an irreversible increase in body fat, 
greater than in RA. Endogenous and exogenous 
exposure to GC negatively aﬀ ects body compo-
sition by increasing the WHR. There appears to 
be no additional eﬀ ect on BMD in estrogen-defi -
cient women. 
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lage and ankylosis of the joints. RA can also produce diﬀ use 
infl ammation in the lungs, pericardium, pleura, and sclera, and 
also nodular lesions, most common in subcutaneous tissue 
under the skin. Although the cause of RA is unknown, autoim-
munity plays a pivotal role in its chronicity and progression. 
 Various treatments, including nonpharmacological physical 
therapy and occupational therapy are available. Analgesia (pain-
killers) and anti-infl ammatory drugs, as well as steroids are used 
to suppress symptoms, while disease-modifying antirheumatic 
drugs (DMARDs) are often required to inhibit or halt the under-
lying immune process and prevent long-term damage  [10] . For 
sustained improvement in a chronic disease such as RA, it 
appears that GC must be given more or less continuously  [11] , 
but unwanted signs of hormonal excess have been reported in 
40  % of cases at some time, during the course of treatment. Most 
of them are considered mild or transient and disappear or lessen 
if the doses of GC are reduced, often followed also by a decline in 
the degree of improvement  [11] . 
 Few data are available on body composition parameters in CS 
and no data are available on the comparison of body composi-
tion parameters in endogenous versus exogenous GC exposure. 
While CS is a rare condition, exposure to exogenous GC is a com-
mon situation in clinical practice, for a variety of causes. It can 
be assumed that no ideal group of healthy women taking GC 
chronically can exist. Thus, when considering a group of CS 
patients we selected those with RA, since both these conditions 
predominate in females, who are not associated with malig-
nancy and have chronic diseases treated in ambulatory care. 
 The aim of this study was to compare body composition param-
eters after exposure to endogenous hypercortisolism (due to 
Cushing ’ s syndrome) and exogenous GC treatment (with low-
dose prednisone in rheumatoid arthritis) with healthy controls. 
 Patients and Methods 
 ▼ 
 Patients 
 A total of 51 women with CS were included (mean age 51.4  ±  13.5 
years). At the time of the study, 14 CS patients were hypercorti-
solemic (i.  e., active, 12 of pituitary and 2 of adrenal origin) and 
37 were in remission (i.  e., cured, 27 of pituitary and 10 of adre-
nal origin). CS was considered in remission if either adrenal 
insuﬃ  ciency was demonstrated [basal AM cortisol   <  100  nmol / l 
(  <  4  μ g / dl) and / or undetectable 24-h free urinary cortisol] or 
morning cortisol suppression (  <  50  nmol / l,   <  1.8  μ g / dl) after 1  mg 
dexamethasone overnight was observed. Of the 37 in remission, 
10 were adrenal insuﬃ  cient at the time of the evaluation and 
required substitution therapy with hydrocortisone (mean of 
20  mg every day), while the other 27 had presented transient 
hypocortisolism after surgery, but did not currently require sub-
stitution therapy. 
 The mean time of hormonal cure since normalization of cortisol 
to study date was 11  ±  6 years (range, 0.7 – 22 years). The mean 
duration of endogenous hypercortisolism was 70  ±  5 months. 
Duration of hypercortisolism was considered as the period of 
time between symptoms onset (as referred by the patients) and 
the diagnosis of CS plus the period of time between diagnosis 
and remission of hypercortisolism after treatment. Information 
on pituitary function (GH, IGF-I, TSH, free T4, prolactin) and 
estrogen status were collected. 7 patients were GH-defi cient (3 
of them were treated with recombinant human GH), 5 were 
hypothyroid (all on L-thyroxine replacement), 25 were estrogen-
defi cient (17 cured and 8 active, 2 gonadotropin defi cient, 23 
menopausal), while the other 26 were estrogen-suﬃ  cient (20 
cured, 6 active). 
 26 women with RA (mean age 62.0  ±  10.1 years) who required 
treatment with low doses of prednisone (5  mg every day or 
10  mg every 2 days) were included, from the Rheumatology 
Department of our hospital. Diagnostic criteria for RA are those 
proposed by the American College of Rheumatology (ACR) for 
classifi cation of the disease  [12] . 
 Mean duration of exogenous GC treatment was 65  ±  6 months. 
This dose of prednisone was chosen since 5  mg prednisone is 
considered to be equivalent to 20  mg of hydrocortisone  [13] . 
 Information on thyroid function and estrogen status was col-
lected: 3 were hypothyroid (all on L-thyroxine replacement), 22 
were estrogen-defi cient (menopausal), and 4 were estrogen-suf-
fi cient ( Table 1 ). 
 78 healthy control women, (mean age 53.71  ±  12.97 years), were 
selected from the blood donors ’ database at our hospital. They 
have routine blood test and a complete medical history at our 
hospital. Letters were sent to controls, and a phone call was 
made one week later; the fi rst control to accept was included. 
Controls that referred GC treatment or malignant diseases were 
excluded. 
 All patients and controls signed an informed consent after study 
approval by the hospital ethics committee. 
 Methods 
 Lumbar spine and whole body bone mineral density (BMD) and 
body composition [lean body mass LBM), whole and trunkal fat 
mass (FM) and total mass] were measured by dual-energy X-ray 
absorptiometry scanning (DEXA, Delphi QDR 4500, Hologic, Vil-
voorde, Belgium) in both patients and controls. The mean preci-
 Table 1  Clinical parameters in 
patients with Cushing’s syndrome 
and rheumatoid arthritis 
  CS 
 (n  =  51) 
 RA 
 (n  =  26) 
 Age (years)  51.4  ±  13.5  62.0  ±  10.1 
 Duration of endogenous hypercortisolism (months)  70  ±  5  – 
 Duration of exogenous GC treatment (months)  –  65  ±  6 
 Clinical control  Cured  =  37, Active  =  14  – 
 Adrenal insuﬃ  ciency, requiring hydrocortisone 
(20  mg / day) 
 10  – 
 Estrogen status  Estrogen defi cient  =  25 
 Estrogen suﬃ  cient  =  26 
 Estrogen defi cient  =  22 
 Estrogen suﬃ  cient  =  4 
 GH status  GH defi cient  =  7 (3 on replacement 
therapy) 
 GH suﬃ  cient  =  44 
 – 
 GC: glucocorticoid; GH: growth hormone 
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sion error (coeﬃ  cient of variation) was 1  % . Furthermore, 
anthropometric parameters (weight, height, body mass index, 
waist, and hip circumference) and sitting blood pressure (BP) 
were measured. 
 Statistical analysis 
 Quantitative data are expressed as mean and SD (Gaussian dis-
tribution). Data distribution was analyzed by the Kolmogorov –
 Smirnov test. Comparisons between 3 groups were performed 
fi rstly with an ANOVA and ANCOVA tests (using age as covariant) 
to correct for age diﬀ erences between the groups. If the com-
parisons showed signifi cant diﬀ erences, pairwise comparisons 
were done as a Bonferroni post-hoc test. Secondly, comparisons 
between the estrogen defi cient patients in each group were per-
formed with an ANOVA and Bonferroni post hoc test. A p-value 
of   <  0.05 was considered signifi cant. Analysis was performed 
using SPSS 17.0 statistical package for Windows (SPSS Inc., Chi-
cago, IL, USA). 
 Results 
 ▼ 
 Comparisons between rheumatoid arthritis (RA) 
patients and controls 
 Patients with RA had a greater waist-hip ratio (p  <  0.01) and less 
lean body mass (LBM) (p  <  0.01) and lumbar BMD (p  <  0.01) than 
controls ( Table 2 ). 
 Comparisons between Cushing ’ s syndrome (CS) 
patients and controls 
 Patients with CS as a whole group had more total fat [both in 
percentage (p  <  0.01) and in kg (p  =  0.05)] and trunk fat [both in 
percentage (p  <  0.01) and in kg (p  <  0.01)], waist (p  =  0.02), and a 
greater waist-hip ratio (p  <  0.01) than controls. CS patients had 
less whole body-BMD (p  <  0.05) and lumbar BMD (p  <  0.05) than 
controls ( Table 2 and   ● ▶  Fig. 1 ) . When CS patients were divided 
into  “ cured ” and  “ active ” , the above diﬀ erences were maintained 
with respect to controls; additionally cured CS had less LBM 
than controls ( Table 3 ). Active CS had a greater waist-hip ratio 
(p  <  0.05) and less lumbar BMD (p  <  0.01) than cured CS. 
 Regarding cured CS patients that were adrenal insuﬃ  cient at the 
time of the DEXA evaluation and required substitution therapy 
with hydrocortisone, they had less LBM, whole body-BMD and 
lumbar BMD, more trunk fat in percentage and a greater waist-
hip ratio than controls (p  <  0.05, p  <  0.01, p  <  0.05, respectively). 
Additionally they had less lumbar BMD than the cured CS 
patients (p  <  0.01) who did not require hydrocortisone substitu-
tion ( Table 4 ) . 
 Cured CS patients who did not require hydrocortisone substitu-
tion had more total fat [both in percentage (p  <  0.01) and in kg 
(p  <  0.01)] and trunk fat [both in percentage (p  <  0.01) and in kg 
 Table 2  Body composition parameters in patients with Cushing’s syndrome and rheumatoid arthritis and controls a 
  CS 
 (n  =  51) 
 RA 
 (n  =  26) 
 Controls 
 (n  =  78) 
 p 1  p 2  p 3 
 BMI (kg / m 2 )  27.8  ±  6.0  26.3  ±  5.9  26.2  ±  5.3  0.36  1.00  0.86 
 Waist hip ratio  0.90  ±  0.0  0.94  ±  0.2  0.83  ±  0.6   <  0.01   <  0.01  0.31 
 Total fat mass (  % )  39.7  ±  7.0  37.8  ±  7.0  35.5  ±  7.0   <  0.01  0.89   <  0.05 
 Total fat mass (kg)  27.6  ±  10.1  23.5  ±  8.1  23.8  ±  7.8  0.05  0.15   <  0.05 
 Trunk fat mass (  % )  40.7  ±  8.5  36.8  ±  8.3  34.0  ±  8.7   <  0.01  0.81   <  0.01 
 Trunk fat mass (kg)  14.2  ±  5.7  12.2  ±  6.5  11.2  ±  4.5   <  0.01  0.77  0.10 
 Lean body mass (kg)  38.2  ±  5.9  35.4  ±  5.1  39.7  ±  4.2  0.10   <  0.01  0.20 
 Whole-BMD (g / cm 2 )  1.04  ±  0.1  1.1  ±  0.2  1.1  ±  0.1   <  0.05  0.19   <  0.05 
 Lumbar BMD (g / cm 2 )  1.02  ±  0.2  0.9  ±  1.2  1.1  ±  1.2   <  0.05   <  0.01  0.13 
 a p 1  between CS and controls; p 2  between RA and controls; p 3  between CS and RA 












































 Fig. 1   a : Waist-hip ratio (WHR) in patients and controls:  *  p  <  0.01, 
between CS and controls and between RA and controls.  b : Total fat and 
trunk fat mass (percentage) in patients and controls. Total fat mass: 
 *  p  <  0.01 between CS and controls;  * *  p  <  0.05 between CS and RA. Trunk 
fat mass:  *  p  <  0.01 between CS and controls and between CS and RA. 
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(p  <  0.01)], and a greater waist-hip ratio (p  <  0.01) than controls 
( Table 3 ). On the other hand they had a greater lumbar BMD 
(p  <  0.01) than CS patients that required substitution therapy 
with hydrocortisone ( Table 4 ). 
 Comparisons between CS and RA patients 
 CS patients had more total fat (both in percentage and in kg) and 
trunk fat in percentage and less whole body BMD than patients 
with RA (p  <  0.05, p  <  0.01, p  <  0.05, respectively) ( Table 2 
and   ● ▶  Fig. 1 ). 
 Cured CS patients, both globally and those cured who did not 
require hydrocortisone, had more total fat [both in percentage 
(p  <  0.05) and in kg (p  <  0.05)], trunk fat in percentage (p  <  0.01 
and p  <  0.05), lumbar BMD (p  <  0.05 and p  <  0.01) than RA 
patients. Additionally the global CS group also had less whole 
body-BMD (p  <  0.05) than RA patients. Patients with active CS 
had less whole body-BMD and more LBM than RA patients 
(p  <  0.05 and p  =  0.01 respectively) ( Table 3 ) . 
 Cured CS patients still requiring hydrocortisone substitution 
therapy only diﬀ ered from RA patients by a smaller waist-hip 
ratio (p  <  0.01), but were otherwise not diﬀ erent in any of the 
other body composition parameters evaluated ( Table 4 ). No dif-
ferences in BMI within the 3 studied groups were observed. 
 Table 4  Body composition parameters in patients with cured Cushing’s syndrome (with and without replacement therapy with hydrocortisone) and rheuma-
toid arthritis a 
  Cured CS with HC 
 (n  =  10) 
 Cured CS without HC 
 (n  =  27) 
 p 1  p 2  p 3  p 4  p 5 
 BMI (kg / m 2 )  26.7  ±  5.6  27.7  ±  6.4  1.00  1.00  1.00  1.00  1.00 
 Waist hip ratio  0.89  ±  0.0  0.90  ±  0.0   <  0.05   <  0.01   <  0.01  0.82  1.00 
 Total fat mass (  % )  38.5  ±  7.2  40.2  ±  7.5  0.60   <  0.01  0.07   <  0.05  0.92 
 Total fat mass (kg)  25.1  ±  12.9  28.4  ±  10.4  0.80   <  0.01  0.07   <  0.05  0.35 
 Trunk fat mass (  % )  40.4  ±  8.8  40.1  ±  9.2   <  0.05   <  0.01  0.08   <  0.05  0.66 
 Trunk fat mass (kg)  13.1  ±  6.6  14.6  ±  6.1  0.32   <  0.01  0.72  0.15  0.39 
 Lean body mass (kg)  35.9  ±  9.4  38.3  ±  5.0   <  0.05  0.16  0.20  0.14  0.34 
 Whole-BMD (g / cm 2 )  1.01  ±  1.1  1.07  ±  0.9   <  0.01  0.11  0.07  0.10  0.08 
 Lumbar BMD (g / cm 2 )  0.9  ±  1.1  1.1  ±  1.1   <  0.01  0.92  0.06   <  0.01   <  0.01 
 a  p 1  between cured CS with hydrocortisone (HC) and controls; p 2  between cured CS without HC and controls; p 3  between cured CS with HC and RA; p 4  between cured CS 
without HC and RA; p 5  between cured CS without HC and cured CS with HC 
 A p-value of   <  0.05 was considered signifi cant. For controls and RA values see  Table 2 
 Table 5  Body composition parameters in estrogen defi cient (Estrogen – )patients with Cushing’s syndrome, rheumatoid arthritis and controls a 
  Estrogen – CS 
 (n  =  25) 
 Estrogen – RA 
 (n  =  22) 
 Estrogen – controls 
 (n  =  40) 
 p 1  p 2  p 3 
 Age  60.2  ±  10.7  65.6  ±  7.1  61.5  ±  7.1  1.00  1.00  1.00 
 BMI (kg / m 2 )  29.3  ±  5.6  26.8  ±  5.9  28.4  ±  5.4  0.82  0.94  0.80 
 Waist hip ratio  0.90  ±  0.0  0.95  ±  0.21  0.86  ±  0.06   <  0.05   <  0.05  0.55 
 Total fat mass (  % )  41.9  ±  6.1  38.3  ±  6.1  37.7  ±  6.6   <  0.05  1.00   <  0.05 
 Total fat mass (kg)  29.8  ±  10.2  24.0  ±  8.0  26.5  ±  7.9  0.05  0.82   <  0.05 
 Trunk fat mass (  % )  44.4  ±  7.2  37.4  ±  6.8  37.4  ±  7.9   <  0.01  1.00   <  0.01 
 Trunk fat mass (kg)  16.2  ±  5.6  11.5  ±  3.8  13.2  ±  4.4   <  0.01  0.55   <  0.01 
 Lean body mass (kg)  37.7  ±  6.0  35.4  ±  4.5  40.5  ±  4.61  0.10   <  0.01  0.34 
 Whole-BMD (g / cm 2 )  1.02  ±  0.1  1.08  ±  0.1  1.08  ±  0.1  0.30  1.00  0.41 
 Lumbar BMD (g / cm 2 )  1.0  ±  0.2  0.9  ±  0.2  1.04  ±  0.2  1.00  0.72  1.00 
 a   p 1  between estrogen – CS and estrogen – controls; p 2  between estrogen – RA and estrogen – controls; p 3  between estrogen – CS and estrogen – RA 
 A p-value of   <  0.05 was considered signifi cant 
 Table 3  Body composition parameters in patients diagnosed with Cushing’s syndrome (active and cured) and rheumatoid arthritis and controls a 
  Cured CS 
 (n  =  37) 
 Active CS 
 (n  =  14) 
 p 1  p 2  p 3  p 4  p 5 
 BMI (kg / m 2 )  27.4  ±  6.7  28.7  ±  3.1  1.00  0.82  1.00  1.00  1.00 
 Waist hip ratio  0.89  ±  0.5  0.93  ±  0.5   <  0.01   <  0.01  0.35  1.00   <  0.05 
 Total fat mass (  % )  39.7  ±  7.4  39.4  ±  5.9   <  0.01   <  0.01   <  0.05  0.85  0.45 
 Total fat mass (kg)  27.5  ±  11.1  27.7  ±  7.3   <  0.05   <  0.05   <  0.05  0.81  0.21 
 Trunk fat mass (  % )  40.8  ±  9.0  40.4  ±  7.4   <  0.01   <  0.01   <  0.01  0.75  0.15 
 Trunk fat mass (kg)  14.2  ±  6.1  14.3  ±  4.3   <  0.01   <  0.01  0.12  0.82  0.77 
 Lean body mass (kg)  37.7  ±  6.4  39.7  ±  3.9   <  0.05  0.92  0.31  0.01  0.35 
 Whole-BMD (g / cm 2 )  1.05  ±  0.1  1.02  ±  0.7   <  0.01   <  0.01   <  0.05   <  0.05  0.12 
 Lumbar BMD (g / cm 2 )  1.05  ±  1.1  0.9  ±  0.1   <  0.05   <  0.01   <  0.05  0.72   <  0.01 
 a   p 1  between Cured CS and controls; p 2  between Active CS and controls; p 3  between Cured CS and RA; p 4  between Active CS and RA; p 5  between Active CS and Cured CS
A p-value of   <  0.05 was considered signifi cant. For controls and RA values see  Table 2 
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 Role of GH defi ciency 
 When the data were reanalyzed excluding the CS patients with 
GH defi ciency without replacement therapy (n  =  4) the same 
results were found. 
 Role of estrogens 
 Because estrogens play an important role on bone, CS patients, 
RA patients and controls were divided into an estrogen-suﬃ  -
cient group (including premenopausal with regular menses and 
postmenopausal women with hormone replacement therapy) 
and an estrogen-defi cient group (including postmenopausal and 
premenopausal women with no replacement for hypogonad-
ism). When data were reanalyzed comparing only the estrogen-
defi cient groups, all the diﬀ erences in lumbar BMD and whole 
body-BMD disappeared. The other diﬀ erences in body composi-
tion parameters, however, remained the same ( Table 5 ). 
 Discussion 
 ▼ 
 While exposure to endogenous hypercortisolism due to CS is a 
rare situation, chronic treatment with exogenous GC is common 
in clinical practice for a variety of causes. There is a general con-
sensus that the shortest period at the lowest possible dose of GC 
is desirable to prevent side eﬀ ects, but there is little awareness 
that low doses may also be harmful. For this reason we com-
pared body composition after exposure to endogenous hyper-
cortisolism (due to Cushing ’ s syndrome) and exogenous GC 
treatment (with low-dose prednisone in rheumatoid arthritis). 
 Increased total and central body fat is a common feature of CS 
 [14,  15] . Waist-hip ratio is an abdominal fat distribution index, 
predictor of cardiovascular risk  [16] , and is more sensitive than 
BMI to evaluate clustering of coronary risk factors among non-
obese men and women  [16] . Since the women with RA were 
older than those with CS, a statistical analysis using age as cov-
ariant was performed in order to make the groups comparable 
and avoid the eﬀ ect of age. 
 We found that both patients with CS and RA have a higher waist-
hip ratio than controls, with no diﬀ erence between them, conse-
quently indicating a higher cardiovascular risk. This would 
suggest that the waist-hip ratio might be used in clinical practice 
to assess cardiovascular risk both in CS and RA patients. Moreo-
ver, persistence of increased total and central body fat has been 
reported in patients with cured CS  [17,  18] . This increase in 
trunk fat is a common complaint of patients who have suﬀ ered 
from CS and also those who have been treated with high doses of 
exogenous GC. Given the increased cardiovascular risk conferred 
by central obesity, this persistence in trunk fat may contribute to 
long-term morbidity in these patients, despite endocrine con-
trol  [17,  19] . 
 A possible explanation for the persistent increase in trunk fat 
may be the eﬀ ect of cortisol on the omental adipose tissue; after 
hypercortisolism has disappeared, the increased number of fat 
cells, enhanced by cortisol, remains and can contribute to explain 
the persistent increase in abdominal fat deposits  [20 – 22] . A dys-
regulation in the hypothalamic-pituitary-adrenal (HPA) axis 
could also be involved  [23] . Another novel mechanism that 
explains the deposition of visceral adipose tissue and conse-
quent central obesity in patients with iatrogenic or endogenous 
CS is the inhibition of AMPK activity in adipose tissue by GC 
 [24] . 
 The coexistence of GH defi ciency in patients with Cushing ’ s dis-
ease after long-term remission of hypercortisolism obtained by 
surgery, by itself may aﬀ ect body composition  [25 – 27] . Male 
gender and length of hypercortisolism are the most signifi cant 
predictors of postsurgical GH defi ciency; our study only included 
women and few GH defi ciency, these could be the reasons why 
no eﬀ ect of GH defi ciency on body composition was found. 
 Estrogens exert an important eﬀ ect on normal bone density and 
estrogen defi ciency is associated with bone loss  [28] as well as 
an increase in total and trunk fat when compared to healthy con-
trols  [29] . In this study we show that the lower values of BMD in 
CS and RA, when compared to controls, disappeared when only 
estrogen-defi cient women were compared, highlighting that 
once the protective eﬀ ect of estrogen is lost, GC exposure is less 
important for the bone, be it of endogenous or exogenous origin. 
This is clearly diﬀ erent from the eﬀ ect on the fat, since CS has 
greater body fat, independently of the estrogen status; this 
would confer to these patients a persistent higher cardiovascu-
lar risk. 
 The deleterious eﬀ ects of glucocorticoid replacement on bone in 
estrogen-suﬃ  cient women after long-term remission of Cush-
ing ’ s Syndrome has been recently demonstrated; the damage 
done to bone during endogenous hypercortisolism may have 
contributed to determine a worse response to subsequent GC 
replacement  [30] . The exact mechanism is not known, in the lit-
erature the mevalonate pathway is involved in glucocorticoid-
induced osteoblast dysfunction  [31] . 
 Patients with RA had less lean body mass (LBM) than controls 
and less than active CS, even when only estrogen defi cient 
women were compared. Less lean body mass has been described 
in RA  [32] , probably related to less muscle exercise due to articu-
lar pain in these patients. From our study it appears that neither 
GC exposure nor estrogen status play a further role on LBM in 
these RA patients. 
 It is not so clear why CS patients have more severe changes in 
body composition than RA patients. This is the fi rst study to 
address and compare this issue. Since the length of glucocorti-
coid exposure is quite similar, we could hypothesize, based on 
clinical experience and on the literature, that chronic, continu-
ous, throughout 24  h, endogenous exposure over months or 
years to severe hypercortisolism, has a greater eﬀ ect on body 
composition than daily prednisone treatment administrated 
once a day, as occurs in RA. As demonstrated previously  [14] , the 
cumulative exposure to GC in CS does not appear to be a deter-
minant factor. 
 In conclusion, prior exposure to endogenous hypercortisolism in 
CS determines an irreversible increase in body fat, greater than 
that seen in RA treated with low dose prednisone. Endogenous 
and exogenous exposure to GC negatively aﬀ ects body composi-
tion by increasing the waist-hip ratio. There appears to be no 
additional eﬀ ect on BMD in estrogen defi cient women. 
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